The National Cancer Society Malaysia has raised an urgent alarm about the escalating threat of cardio-renal-metabolic diseases, calling on authorities to implement a coordinated national screening framework to address the problem before it overwhelms the healthcare system. The organisation's warning comes amid mounting evidence that these conditions—encompassing heart disease, kidney dysfunction and metabolic disorders like diabetes—are converging in Malaysian populations at alarming rates, with nearly 90 per cent of individuals now carrying two or more associated risk factors simultaneously.
The gravity of the situation became apparent through a major screening initiative conducted across the Klang Valley. The NCSM-Boehringer Ingelheim Saring@Komuniti Project, implemented with backing from the Ministry of Health, evaluated 5,000 individuals from communities with limited healthcare access. The results painted a sobering picture of hidden disease burden lurking within these populations, revealing that interconnected cardiovascular, kidney and metabolic conditions are far more prevalent than routine health statistics typically capture. Almost all participants—97.8 per cent—presented with at least one cardio-renal-metabolic risk factor, suggesting that these diseases have become nearly universal problems in Malaysia rather than exceptions.
The underlying data is particularly striking when examined across specific conditions. The screening found that 41.3 per cent of participants were classified as obese and an additional 28.8 per cent were overweight, meaning nearly 70 per cent carried excessive body weight. Blood sugar abnormalities proved equally concerning, with 34.5 per cent displaying pre-diabetic conditions and 35.1 per cent already diagnosed with diabetes. These figures indicate that blood sugar dysregulation has become entrenched within the population, suggesting years of undiagnosed metabolic damage may already be occurring.
This emerging public health crisis extends beyond immediate screening findings. Malaysia's track record with chronic kidney disease illustrates the trajectory these interconnected conditions follow when left unmanaged. Chronic kidney disease prevalence expanded from just 9.1 per cent in 2011 to 15.5 per cent by 2019—a 70 per cent increase in less than a decade. More dramatically, the number of Malaysians requiring dialysis has more than tripled over the past two decades, representing an explosive growth in end-stage kidney disease cases that reflect years of undetected and unmanaged disease progression.
The fundamental problem lies in how Malaysia's healthcare system approaches these conditions. Rather than recognising that cardiovascular disease, kidney dysfunction and metabolic disorders share common root causes and accelerate one another's advancement, current medical practice treats each condition in isolation. This siloed approach creates substantial blind spots, allowing patients with multiple interconnected risk factors to slip through detection gaps. A patient might receive screening for diabetes without concurrent assessment of cardiovascular or kidney risk, missing opportunities to intervene before complications cascade across multiple organ systems.
Beyond fragmented screening practices, the pathway from detection to long-term management remains fractured. Even when abnormal screening results identify disease risk, inconsistent follow-up systems and fragmented referral networks frequently prevent patients from accessing timely treatment. Some individuals bounce between different healthcare providers without coordinated care plans, while others face bureaucratic obstacles that delay interventions. Without structured mechanisms ensuring that screening results translate into actual diagnosis and sustained management, screening programmes yield minimal health improvement.
The NCSM's policy recommendations target these systemic deficiencies head-on. The organisation proposes expanding integrated co-screening programmes throughout Malaysia, embedding standardised cardio-renal-metabolic risk assessments into routine health checks that all Malaysians receive. Rather than screening for individual diseases separately, integrated assessment would simultaneously evaluate cardiovascular risk, kidney function and glucose metabolism, capturing the interconnected nature of these conditions. Additionally, the framework would strengthen referral pathways and follow-up mechanisms to ensure that screening identification translates into diagnosis, treatment initiation and sustained long-term disease management.
Dr Murallitharan Munisamy, Managing Director of NCSM, emphasised that Malaysia stands at a critical juncture regarding chronic disease management. The current trajectory—with rising chronic kidney disease prevalence, exploding dialysis demands and widespread metabolic dysfunction—remains unsustainable without fundamental healthcare restructuring. He articulated that the country must transition from managing isolated diseases toward recognising cardiovascular, kidney and metabolic health as an integrated continuum requiring coordinated detection and care. Early identification without subsequent management provides minimal benefit; detection must be paired with structured follow-up and enduring care pathways if outcomes are to improve and the chronic disease burden is to stabilise.
Cheong Yee Kok, General Manager and Head of Human Pharma at Boehringer Ingelheim Malaysia, Singapore, and Indonesia, underscored the fundamental biological reality driving these recommendations. Cardiovascular, kidney and metabolic conditions share common risk factors and amplify each other's impact, meaning interventions addressing one condition frequently benefit others simultaneously. This interconnectedness suggests that integrated screening and management approaches could yield substantial efficiency gains, potentially preventing or delaying disease progression more effectively than isolated interventions.
The timing of NCSM's call aligns with accelerating chronic disease trends throughout Malaysia. Beyond kidney disease escalation, obesity prevalence has climbed steadily, diabetes affects millions, and hypertension remains inadequately controlled in many communities. These conditions increasingly cluster within individuals rather than appearing in isolation, creating compounding health impacts that fragment care systems struggle to manage. Healthcare experts caution that without earlier detection and coordinated intervention, patient burdens will intensify alongside healthcare system strain.
For Malaysian policymakers and health administrators, the NCSM's recommendations provide a concrete roadmap for systemic improvement. Scaling cardio-renal-metabolic co-screening nationwide requires investment in training healthcare workers, upgrading laboratory and diagnostic capacity, and establishing referral networks linking primary care to specialist services. Embedding standardised risk assessments into routine health checks requires revising health check protocols across government clinics and occupational health programmes. Strengthening referral and follow-up mechanisms demands technological investments in health information systems enabling care coordination across fragmented provider networks.
The broader implications for Southeast Asia extend beyond Malaysia's borders. As regional economies develop and populations adopt increasingly sedentary lifestyles with processed food consumption, cardio-renal-metabolic disease prevalence is rising throughout the region. Early data from screening programmes comparable to NCSM's initiative would likely reveal similar patterns of hidden disease burden across Southeast Asian nations. Malaysia's response to this challenge—whether through integrated screening frameworks or continued fragmented approaches—may offer instructive lessons for neighbouring countries facing identical pressures.
Ultimately, the National Cancer Society Malaysia's intervention represents a plea for healthcare system transformation grounded in epidemiological reality. The screening data unambiguously demonstrates that cardio-renal-metabolic diseases have become interwoven within Malaysian populations rather than existing as separate challenges. Current healthcare infrastructure, designed around individual disease management, cannot adequately address this reality. Without adopting integrated screening and care approaches, Malaysia will face continued escalation in chronic disease burden, expanding healthcare expenses, and diminishing population quality of life—outcomes that comprehensive screening strategy implementation could substantially mitigate.
